Beam-induced backgrounds in the CLIC 3 TeV CM energy interaction region

Luminosity spectrum and accelerator background levels strongly influence the experimental conditions and have an important impact on detector design. The expected rates of the main beam-beam products at CLIC 3 TeV CM energy, taking into account for machine imperfections, are computed. Among the other machine-induced background the photon fans from the Incoherent Synchrotron Radiation (ISR) photons emitted in the final doublet are evaluated.Comment: Proceedings of LCWS1

Regular Incidence Complexes, Polytopes, and C-Groups

Regular incidence complexes are combinatorial incidence structures generalizing regular convex polytopes, regular complex polytopes, various types of incidence geometries, and many other highly symmetric objects. The special case of abstract regular polytopes has been well-studied. The paper describes the combinatorial structure of a regular incidence complex in terms of a system of distinguished generating subgroups of its automorphism group or a flag-transitive subgroup. Then the groups admitting a flag-transitive action on an incidence complex are characterized as generalized string C-groups. Further, extensions of regular incidence complexes are studied, and certain incidence complexes particularly close to abstract polytopes, called abstract polytope complexes, are investigated.Comment: 24 pages; to appear in "Discrete Geometry and Symmetry", M. Conder, A. Deza, and A. Ivic Weiss (eds), Springe

First Evaluation of Dynamic Aperture at Injection for FCC-hh

In the Hadron machine option, proposed in the context of the Future Circular Colliders (FCC) study, the dipole field quality is expected to play an important role, as in the LHC. A preliminary evaluation of the field quality of dipoles, based on the Nb$_{3}$Sn technology, has been provided by the magnet group. The effect of these field imperfections on the dynamic aperture, using the present lattice design, is presented and first tolerances on the b$_3$ and b$_5$ multipole components are evaluated

Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in cushing's syndrome

We determined the adrenostatic potential of low-dose nonhypnotic etomidate in six patients with Cushing's syndrome (ectopic Cushing's syndrome,n=2; Cushing's disease,n=3; bilateral adrenal adenoma,n=1). Etomidate was given as a continuous infusion for 32 h in a dose of 2.5 mg/h (n=5) or 0.3 mg/kg/h (n=3), respectively. Saline was given during a control period. The responsiveness to exogenous ACTH was studied during placebo and 7 and 31 h after commencing etomidate by administration of 250 µg 1–24 ACTH i.v. Etomidate (2.5 mg/h) led to a consistent decrease in serum cortisol in all patients from a mean of 39.4±13.3 to 21.1±5.7 µg/dl after 7 h (P<0.05 compared with placebo). After 24 h cortisol was reduced further to a mean steady state concentration of 12.3±5.7 µg/dl (P<0.05). At the end of the infusion period the cortisol increase in response to ACTH was reduced but not abolished. In contrast, a dose of 0.3 mg/kg/h etomidate induced unresponsiveness of serum cortisol to exogenous ACTH within 7 h. However, sedation was observed in two out of three patients at this dose, while during etomidate in a dose of 2.5 mg/h no side effects were seen. We conclude that low-dose non-hypnotic etomidate reduces serum cortisol to within the normal range in patients with Cushing's syndrome. The possibility to dissociate the adrenostatic effect of etomidate from its hypnotic action, the absence of side effects, and the i.v. route suggest that etomidate in a dose of 0.04–0.05 mg/kg/h may become the drug of choice for rapid initial control of hypercortisolism

Ca II and Na I Quasar Absorption-Line Systems in an Emission-Selected Sample of SDSS DR7 Galaxy/Quasar Projections: I. Sample Selection

The aim of this project is to identify low-redshift host galaxies of quasar absorption-line systems by selecting galaxies which are seen in projection onto quasar sightlines. To this end, we use the Seventh Data Release of the Sloan Digital Sky Survey (SDSS-DR7) to construct a parent sample of 97489 galaxy/quasar projections at impact parameters of up to 100 kpc to the foreground galaxy. We then search the quasar spectra for absorption line systems of Ca II and Na I within +- 500 km/s of the galaxy's velocity. This yields 92 Ca II and 16 Na I absorption systems. We find that most of the Ca II and Na I systems are sightlines through the Galactic disk, through High Velocity Cloud complexes in our halo, or Virgo cluster sightlines. Placing constraints on the absorption line rest equivalent width significance (>=3.0 sigma), the Local Standard of Rest velocity along the sightline (>= 345 km/s), and the ratio of the impact parameter to the galaxy optical radius (<=5.0), we identify 4 absorption line systems that are associated with low-redshift galaxies at high confidence, consisting of two Ca II systems (one of which also shows Na I), and two Na I systems. These 4 systems arise in blue, L_r^* galaxies. Tables of the 108 absorption systems are provided to facilitate future follow up.Comment: 13 pages, 11 figures, 6 tables; online data included in electronic version as 1 FITS table and 2 machine readable tables; to be published in The Astronomical Journa

Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living : a pooled analysis of two randomized controlled trials

Objective: To evaluate the impact of onabotulinumtoxinA on individual domains of the quality of life questionnaires in a pooled analysis of two phase 3 trials in overactive bladder patients with urinary incontinence who were inadequately managed by >= 1 anticholinergic. Methods: Patients received intradetrusor injections of onabotulinumtoxinA 100U (n = 557) or placebo (n = 548). The proportions of patients with a positive response (condition "greatly improved" or "improved") on the Treatment Benefit Scale, and changes in Incontinence Quality of Life scores and King's Health Questionnaire domain scores were analyzed in the overall population and subgroups with clean intermittent catheterization use and urinary tract infection status during the first 12 weeks of treatment. Responses to individual King's Health Questionnaire items were also assessed. Results: Significantly greater proportions of onabotulinumtoxinA-treated patients achieved positive Treatment Benefit Scale response versus placebo (61.8% vs 28.0%; P < 0.001). OnabotulinumtoxinA showed significantly greater improvements versus placebo in Incontinence Quality of Life total (22.5 vs 6.6), Incontinence Quality of Life subscale scores and all domains of the King's Health Questionnaire. Notably, a similar trend was observed regardless of clean intermittent catheterization/urinary tract infection status. Additionally, onabotulinumtoxinA resulted in significantly greater improvements than the placebo in practical aspects of patients daily lives, including pad use, need to change undergarments, sleep, relationship with partner and work life/daily activities. Conclusion: In overactive bladder patients with urinary incontinence, onabotulinumtoxinA 100U demonstrated significant improvements across the individual domains of the quality of life questionnaires, regardless of clean intermittent catheterization or urinary tract infection status, and provided a positive impact on practical aspects of patients' daily lives